Log in with your social account Forgot Password ? An Indonesian aircraft that will bring Indonesian citizens home from Wuhan, China, took off from Soekarno-Hatta International Airport in Tangerang, Banten, on Saturday at approximately 1:10 p.m.The Batik Air Airbus A330-300 with a 392-seat capacity will evacuate 250 Indonesian citizens from Hubei province following the coronavirus outbreak.The evacuation team consists of 42 people, including nine cabin crew members, a pilot, a co-pilot and representatives from the Foreign Ministry, Health Ministry and Indonesian Military (TNI).”Our citizens, who live in Enshi city [542 kilometers from Wuhan], Jingzhou city [222 km from Wuhan], Huangshi city [100 km from Wuhan] and Xianning city [98 km from Wuhan], will gather at Wuhan Airport to be picked up,” Foreign Minister Retno Marsudi said at a press conference at Soekarno-Hatta International Airport on Saturday.According … Google Facebook Topics : LOG INDon’t have an account? Register here Linkedin Wuhan-coronavirus Wuhan-coronavirus-in-Indonesia Wuhan-lockdown evacuation Batik-Air Indonesian Retno-Marsudi Soekarno-Hatta-International-Airport Natuna
Topics : Shares in the company rose 2.5% in premarket trading.The drug is already being tested in hospitals to study whether it can work as a treatment in patients who have the disease. This trial will test whether it works prophylactically.The phase 3 nursing homes trial is being conducted in partnership with several long-term care networks across the country as well as the US National Institute of Allergy and Infectious Diseases (NIAID).To speed the study, Eli Lilly has created mobile research units including retrofitted recreational vehicles that can be deployed in response to coronavirus outbreaks at nursing homes across the USLY-CoV555 belongs to a class of treatments known as monoclonal antibodies, which are among the most widely used biotechnology medicines. Regeneron Pharmaceuticals Inc and other drugmakers are testing similar treatments against COVID-19.Last week Lilly told investors that LY-CoV555 had moved into mid-stage trials as a treatment and that late-stage trials would begin in the coming weeks. It expects efficacy data from the mid-stage trial in the fourth quarter. US drugmaker Eli Lilly & Co is beginning a late-stage trial to study whether one of its experimental COVID-19 antibody treatments can prevent the spread of the virus in residents and staff at US nursing homes, it said on Monday.The phase 3 trial will test LY-CoV555, a treatment developed in partnership with Canadian biotech company AbCellera, is expected to enroll up to 2,400 participants who live or work at a facility that has had a recently diagnosed case of COVID-19.”COVID-19 has had a devastating impact on nursing home residents,” Eli Lilly’s chief scientific officer, Daniel Skovronsky, said in a statement. “We’re working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals.”
Posted in ziyevidgTagged: 2020上海最新夜上海论坛, 上海yldt8, 上海夜网SC, 上海夜网SD, 上海夜网TP, 上海夜网XJ, 夜上海论坛FJ, 宁波600品茶, 宁波哪些酒店可以叫服务, 松江大学城如何约, 爱上海JH, 阿拉爱上海1314.